Enveric Biosciences (NASDAQ: ENVB) announced that the U.S. Patent and Trademark Office (USPTO) has granted a second Notice of Allowance for novel compounds within its next-generation, non-hallucinogenic mescaline derivatives in the EVM401 Series.
According to Enveric, the second patent allowance serves to expand the company’s intellectual property assets in the treatment of mental health disorders.
In a statement, Joseph Tucker, PhD, director and CEO of Enveric, commented, “With this second patent allowance for the EVM401 Series, Enveric continues to strengthen its position as a first-in-class developer of neuroplastogenic small-molecule therapeutics. These patent-protected molecules are designed to capture the desirable neuroplasticity-promoting effects of methylone, while offering novel chemical structures that enable both strong IP protection and a potential path to repeat-dose outpatient care.”
